Portfolio company
OPS-γδ
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops an engineered gamma delta T cell therapy platform to treat patients with solid tumours.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
OverT
This biotechnology company develops engineered cell therapies for the treatment of solid tumours in cancer patients.
Captain T Cell
The company develops cell therapies for cancer patients to treat solid tumours.
LAVA Therapeutics
The company develops bispecific antibodies that engage gamma-delta T cells to treat hematological and solid cancers.
OverT Bio
This company develops engineered cell therapies and genetic screening platforms to treat patients with solid tumour cancers.
Ypsilon Therapeutics
The company develops T-cell receptor mimic antibodies and bispecific T-cell engagers to treat patients with solid tumours, such as triple-negative breast and lung cancer.
ArsenalBio
The company develops programmable T cell therapies for patients with solid tumours and autoimmune diseases.
PanCancerT
This biotech company develops T-cell receptor therapies for patients with solid tumours, focusing on targets like triple-negative breast cancer and melanoma.
CTRL Therapeutics
This company develops cell therapies for solid tumours and microfluidic platforms to identify rare tumour-reactive lymphocytes for cancer patients.